Medical Device Global Market Access

Pure Global
  • 5.0 (1)
  • Technology

Navigate every market. Accelerate every launch. Medical Device Global Market Access by Pure Global is the audio briefing that turns the world’s most confusing regulatory pathways into clear, actionable roadmaps. If you’re a MedTech founder, RA/QA leader, product manager, or investor who needs to get devices cleared anywhere from Austin to Abu Dhabi, this show is your shortcut. Why listen? • Step-by-step playbooks – We decode EU MDR, U.S. 510(k), Brazil’s ANVISA, China’s NMPA, and 25 + other regimes, showing exactly how long each milestone really takes and where companies get stuck. • First-hand war stories – Hear candid interviews with regulatory veterans who have shepherded implants, software, wearables, diagnostics, and AI algorithms to market—and lived to tell the tale. • Real-time intelligence – Every episode covering the week’s new guidances, standards, and enforcement trends so you’re always ahead of the curve. • Actionable templates – From clinical evaluation checklists to technical-file skeletons, we break down the documents you’ll need and the pitfalls reviewers love to flag. • AI-powered insights – Because Pure Global mines millions of public filings, tenders, and recalls, we surface data-backed best practices you won’t hear at conferences—or from competitors. What you’ll hear • Launching SaMD under multiple risk classes in parallel • Surviving an unannounced ISO 13485 audit • Building a “reg-first” QMS that scales • Mastering Latin-American registrations without endless language cycles • Leveraging real-world evidence to shorten clinical timelines • Aligning cybersecurity, privacy, and post-market surveillance rules across regions Whether you’re plotting first entry, managing lifecycle expansions, or rescuing a delayed submission, subscribing could shave months—and millions—off your path to revenue. ⸻ Brought to you by Pure Global – the AI-native consultancy that already guides MedTech innovators through regulatory and market-access hurdles in 30 + countries. Ready for expert help on your next submission? Visit https://pureglobal.com or email info@pureglobal.com to start accelerating today.

  1. 21h ago

    UK MHRA AI Scribe Guidance: Clarifying Regulatory Status of AI Medical Scribes

    The UK's MHRA issued guidance on July 29, 2026, clarifying that certain Ambient Voice Technology (AVT), or 'AI scribes,' are not regulated as medical devices if their function is purely administrative. This episode details the specific functions, such as transcription and summarization for clinician review, that fall outside the regulation's scope. We explore how this clarification creates a faster, more streamlined path to the UK market for manufacturers and outline the critical steps that regulatory and quality teams should take in response. Key Questions: - What is the UK MHRA's new guidance on AI scribes and Ambient Voice Technology? - When is an AI scribe officially considered a medical device in the United Kingdom? - Which specific AI functions are now considered non-medical and outside the scope of regulation? - How does this MHRA decision accelerate market access for AI technology in the UK? - What is the crucial difference between a regulated clinical decision support tool and a non-regulated administrative AI? - What are the immediate actions manufacturers should take to align with this new guidance? - Does this UK-specific clarification impact regulatory requirements in the EU or the US? - Why have some medical professional bodies raised concerns about this decision? - How should companies define and document their product's intended purpose to ensure compliance? - What are the risks of misrepresenting a product's function in marketing materials? Sources: - https://www.gov.uk/government/news/mhra-clarifies-regulatory-status-of-ambient-voice-technologies-used-in-the-nhs - https://www.rcplondon.ac.uk/news/rcp-expresses-concern-over-mhra-decision-not-regulate-all-automated-voice-technologies-medical How Pure Global can help: Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access. We develop efficient regulatory strategies, manage technical dossier submissions, and act as your local representative in over 30 markets. Our unique approach combines in-country expertise with advanced AI tools to accelerate product registration and ensure ongoing compliance. Whether you are a startup or a multinational enterprise, we can help you navigate complex regulatory landscapes and get your products to patients faster. Contact us at info@pureglobal.com, visit https://pureglobal.com, or explore our free AI tools and device database at https://pureglobal.ai.

  2. 1d ago

    SFDA Used Medical Device Resale: New Warning and Compliance Rules in Saudi Arabia

    This episode details the Saudi Food and Drug Authority's (SFDA) public warning issued on July 28, 2026, regarding the non-compliant resale, auction, lending, or donation of used medical devices. We explore how this action enforces Article 20 of Regulation No. 1/1443 and what it means for healthcare establishments. We cover the specific requirements, including the need for a valid Medical Device Marketing Authorization (MDMA) and the obligation to transfer complete technical documentation to the new user to ensure device safety and performance. Key Questions: - What did the Saudi Food and Drug Authority (SFDA) announce on July 28, 2026? - Why is the resale or auction of used medical devices a compliance risk in Saudi Arabia? - Which specific regulation governs the handling of used medical devices? - What documentation must be provided when transferring a used medical device? - Does this warning apply to donations and lending as well as sales? - What is a Medical Device Marketing Authorization (MDMA) and is it required for used devices? - What are the potential consequences of non-compliance with SFDA's rules? - What immediate steps should facilities with used medical devices take? Sources: - https://www.lexismiddleeast.com/news/saudi-arabia-sfda-warns-against-resale-of-used-medical-devices/ How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies seeking market access in Saudi Arabia and over 30 other countries. Our local experts and advanced AI tools can help you navigate complex SFDA requirements, including those for used medical devices. We assist with regulatory strategy, technical dossier preparation, and act as your local representative to ensure full compliance. With Pure Global, you can streamline your registration process and maintain your market presence confidently. Learn more about our free AI tools and global database at https://pureglobal.ai or contact us at info@pureglobal.com and https://pureglobal.com.

  3. 2d ago

    UK MHRA AI Scribe Regulation: New Guidance for Ambient Voice Technology

    This episode breaks down the UK MHRA's new guidance issued on July 29, 2026, clarifying when Ambient Voice Technology (AVT), or 'AI Scribes,' are regulated as medical devices. We explain the critical distinction: products for simple transcription or note-drafting with clinician review are not devices, while those supporting diagnosis or automated actions are. We cover the implications for AI developers and NHS providers and outline practical steps for compliance and safe adoption under the UK MDR. Key Questions: - What is Ambient Voice Technology (AVT) or an 'AI Scribe'? - When is an AI Scribe considered a medical device in the UK? - What did the MHRA's new guidance on July 29, 2026, clarify? - How does this affect AI software developers targeting the NHS? - What are the compliance requirements under the UK MDR for regulated AVT products? - What due diligence should healthcare providers perform before adopting AI Scribes? - How does the role of clinician review impact the regulatory status of an AVT product? - What practical steps should manufacturers take to assess their product's classification? Sources: - https://www.gov.uk/government/news/mhra-clarifies-regulatory-status-of-ambient-voice-technologies-used-in-the-nhs How Pure Global can help: Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, helping you navigate complex requirements for Software as a Medical Device (SaMD) and AI-driven technologies. Our experts develop efficient regulatory strategies for market access in the UK and over 30 other countries, managing technical dossier compilation and submission. We act as your local representative, ensuring ongoing compliance through post-market surveillance and continuous regulatory monitoring. To access global markets faster, contact us at info@pureglobal.com or visit https://pureglobal.com. Explore our free AI regulatory tools and global device database at https://pureglobal.ai.

  4. 3d ago

    China NMPA 2026 Guidelines: Navigating 57 New Medical Device Rules

    On July 21, 2026, China's NMPA issued 57 new final guidelines for medical devices in a single day, creating a significant new compliance challenge for manufacturers. This episode explores the scope of these guidelines, which cover a wide range of products from cardiovascular to anesthesiology, and outlines the immediate actions required for both new registrations and renewals. We discuss how these changes impact technical documentation, testing protocols, and clinical evidence, providing practical steps for regulatory and quality teams to ensure continued market access in China. Key Questions: - What is the significance of the NMPA releasing 57 medical device guidelines on July 21, 2026? - Which types of medical devices are most affected by these new Chinese regulations? - How do the 2026 guidelines impact manufacturers with existing products on the Chinese market? - What are the specific requirements for technical documentation and testing reports under the new rules? - What immediate steps should regulatory affairs teams take to prepare for these changes? - How will these guidelines affect the clinical evidence requirements for device registration in China? - What is the best way to conduct a gap assessment against the 57 new NMPA guidelines? - Why is it critical to start preparing for these 2026 requirements now? Sources: - https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHWgbN-41P5qVYbn2EB9zi_X7nt-g8mPTbhrZd9dfPCA4QnktuR-EivnfCYgIiPiUE6ByLjQv9XQfkKQ5U79BpI1SJlcTt_h_3QrRwCM5gqz_1LdOBvTkEj-UdeikdzR69FXDV7sXxsM9QGD-8hww== How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, helping them access global markets faster. We act as a local representative in over 30 countries and develop efficient regulatory strategies to minimize costs and rejections. Our AI-powered platform streamlines the compilation and submission of technical dossiers for markets like China, ensuring your documentation meets the latest NMPA requirements. We help you maintain compliance through continuous regulatory monitoring and post-market surveillance. For support with gap assessments, dossier preparation, or overall China market access strategy, contact us at info@pureglobal.com or visit https://pureglobal.com. Explore our free AI tools and global device database at https://pureglobal.ai.

  5. 4d ago

    TGA AI Medical Device Regulation: Preparing for 2026-2027 Enforcement in Australia

    Australia's Therapeutic Goods Administration (TGA) has issued new guidance clarifying when AI-enabled software is regulated as a medical device (SaMD). This episode breaks down the TGA's focus on intended purpose, the specific evidence required for safety and performance, and why SaMD has been designated a key compliance and enforcement priority for 2026-2027. We outline the practical steps manufacturers must take now to review their product classification, update technical documentation, and prepare for increased regulatory scrutiny in the Australian market. Key Questions: - When does the TGA consider AI software to be a regulated medical device? - What are the new evidence requirements for AI/ML models submitted to the TGA? - Why has the TGA designated SaMD as a compliance priority for 2026-2027? - How should manufacturers update their technical documentation for AI-powered devices? - What specific changes are needed in a Quality Management System to manage the AI lifecycle? - How can companies prepare for increased TGA scrutiny on AI and SaMD? - What are the key differences between general wellness software and regulated SaMD in Australia? Sources: - https://www.claytonutz.com/insights/2026/july/healthcare-software-tga-clarifies-when-ai-will-be-regulated-as-a-medical-device How Pure Global can help: Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access. We act as a local representative in over 30 markets, develop efficient regulatory strategies, and use advanced AI to compile and submit technical dossiers. Our experts help you navigate complex requirements for innovative products like AI-enabled SaMD, ensuring your documentation meets TGA standards for safety, performance, and lifecycle management. Prepare for the 2026-2027 enforcement priority with our expert guidance. Contact us at info@pureglobal.com, visit https://pureglobal.com, or explore our free AI tools and device database at https://pureglobal.ai to accelerate your market entry.

  6. 5d ago

    Malaysia MDA Product Classification: Mandatory Online Submissions by August 2026

    Malaysia's Medical Device Authority (MDA) is mandating fully online submissions for all medical device product classification applications starting August 1, 2026. This episode details the transition to the new Product Classification Application System (PCAS), explains the impact on manufacturers seeking market access in Malaysia, and provides practical steps for regulatory teams to prepare for this digital-only process to avoid delays. Key Questions: - What is the new requirement from Malaysia's Medical Device Authority (MDA)? - When does the mandatory online submission for product classification take effect? - Which new system must manufacturers use for these submissions? - How does this change impact the market access process for medical devices in Malaysia? - Who is affected by this regulatory shift? - What are the practical steps regulatory teams should take to prepare for this transition? - Why is it important to update internal procedures and documentation now? - What should you consider when planning your submission timeline using the new PCAS system? Sources: - https://www.pure-global.com/news/malaysia-mda-online-product-classification-2026 How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, accelerating global market access. We develop efficient regulatory strategies, act as your local representative in over 30 markets, and use advanced AI to compile and manage technical dossiers for submission. Our experts help you navigate complex requirements like Malaysia's new PCAS system, ensuring your submissions are compliant and timely. By partnering with us, you can streamline your registration process and focus on your core business. Contact us at info@pureglobal.com, visit https://pureglobal.com, or explore our free AI tools and device database at https://pureglobal.ai to learn more.

  7. 6d ago

    FDA's MDUFA VI Draft Commitment Letter: Key Proposals and the August 7 Comment Deadline

    This episode details the US FDA's newly released draft commitment letter for the sixth Medical Device User Fee Act (MDUFA VI), which will govern fiscal years 2028 through 2032. We explore the key proposals, including a significant expansion of the Total Product Life Cycle (TPLC) Advisory Program (TAP) Pilot, updated review performance goals, and a focus on digital health. We also highlight the critical public comment deadline of August 7, 2026, and provide practical steps for manufacturers to prepare and respond. Key Questions: - What is the MDUFA VI draft commitment letter and why is it important for medical device manufacturers? - Which fiscal years will the new MDUFA VI agreement cover? - How is the FDA proposing to expand the Total Product Life Cycle (TPLC) Advisory Program (TAP) Pilot? - What is the critical deadline for submitting public comments on the draft letter? - Who is most affected by the proposed changes in MDUFA VI? - What are the key performance goals and policy changes outlined in the draft? - How can early engagement through the TAP program benefit device sponsors? - What practical steps should regulatory teams take right now to prepare? Sources: - https://www.hklaw.com/en/insights/publications/2026/07/fda-releases-draft-commitments-letter-for-medical-devices-review - https://www.fda.gov/news-events/cdrh-new-news-and-updates How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies seeking to access global markets. Our experts develop efficient pathways for regulatory approval, including U.S. FDA submissions, and help clients navigate complex policy changes like MDUFA VI. We offer services in regulatory strategy, technical dossier preparation, and local representation in over 30 countries. By leveraging our advanced AI tools and global network, we streamline the registration process, helping you get to market faster. For support with your global market access strategy, visit us at https://pureglobal.com, contact us at info@pureglobal.com, or explore our free AI tools and device database at https://pureglobal.ai.

  8. Jul 27

    South Korea MFDS Proposal for Digital Medical Device Testing: What Manufacturers Need to Know

    South Korea's Ministry of Food and Drug Safety (MFDS) has released Legislative Notice No. 2026-341, a proposal to amend the rules for medical device testing. This episode breaks down the most significant change: officially allowing medical device testing institutions to test digital medical devices, including Software as a Medical Device (SaMD) and AI-based technologies. We discuss what this means for manufacturers seeking market access in South Korea, the revised administrative penalty criteria for testing labs, and the crucial public comment deadline of September 14, 2026. Key Questions: - What is Legislative Notice No. 2026-341 from South Korea's MFDS? - How will this proposal change testing requirements for digital medical devices in South Korea? - Which types of devices, like SaMD and AI-based software, are impacted? - Why is the MFDS formalizing the role of medical device testing institutions for these products? - What are the revised administrative penalty criteria for testing institutions? - What is the deadline for submitting public comments on this proposal? - What practical steps should digital health manufacturers take now in response to this notice? - How can companies prepare their technical documentation for these new testing pathways? Sources: - https://www.foodmate.com/news/korea/413031.html How Pure Global can help: Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access. We act as your local representative in over 30 markets, develop efficient regulatory strategies, and use advanced AI to compile and manage technical dossiers for submission. Our team of local experts provides continuous regulatory monitoring to ensure your products remain compliant long after approval. Whether you are a startup or a multinational enterprise, Pure Global provides the strategic support and technology-driven solutions needed to access global markets faster. Contact us at info@pureglobal.com or visit https://pureglobal.com. Explore our free AI-powered regulatory tools and database at https://pureglobal.ai.

See All (390)

About

Navigate every market. Accelerate every launch. Medical Device Global Market Access by Pure Global is the audio briefing that turns the world’s most confusing regulatory pathways into clear, actionable roadmaps. If you’re a MedTech founder, RA/QA leader, product manager, or investor who needs to get devices cleared anywhere from Austin to Abu Dhabi, this show is your shortcut. Why listen? • Step-by-step playbooks – We decode EU MDR, U.S. 510(k), Brazil’s ANVISA, China’s NMPA, and 25 + other regimes, showing exactly how long each milestone really takes and where companies get stuck. • First-hand war stories – Hear candid interviews with regulatory veterans who have shepherded implants, software, wearables, diagnostics, and AI algorithms to market—and lived to tell the tale. • Real-time intelligence – Every episode covering the week’s new guidances, standards, and enforcement trends so you’re always ahead of the curve. • Actionable templates – From clinical evaluation checklists to technical-file skeletons, we break down the documents you’ll need and the pitfalls reviewers love to flag. • AI-powered insights – Because Pure Global mines millions of public filings, tenders, and recalls, we surface data-backed best practices you won’t hear at conferences—or from competitors. What you’ll hear • Launching SaMD under multiple risk classes in parallel • Surviving an unannounced ISO 13485 audit • Building a “reg-first” QMS that scales • Mastering Latin-American registrations without endless language cycles • Leveraging real-world evidence to shorten clinical timelines • Aligning cybersecurity, privacy, and post-market surveillance rules across regions Whether you’re plotting first entry, managing lifecycle expansions, or rescuing a delayed submission, subscribing could shave months—and millions—off your path to revenue. ⸻ Brought to you by Pure Global – the AI-native consultancy that already guides MedTech innovators through regulatory and market-access hurdles in 30 + countries. Ready for expert help on your next submission? Visit https://pureglobal.com or email info@pureglobal.com to start accelerating today.

Information